MedPath

Evaluation of oxytocin treatment in children with autism and intellectual disability’, Multiple-dose Oxytocine - ASD and Intellectual Disability

Recruiting
Conditions
Autism spectrum disorder (ASD)
Registration Number
2024-513436-14-00
Lead Sponsor
UZ Leuven
Brief Summary

To evaluate the efficacy of multiple-dose oxytocin treatment on core autism symptoms using standardized assessments in children with ASD and comorbid ID.

Change from baseline after oxytocin administration on:

-Behavioral measurements of core autism (social) symptoms

-Cardio electrophysiological measurements of stress

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing, recruiting
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

Children within an age-range of 4 to 13 years old with a clinical multidisciplinary diagnosis of ASD; only premenstrual girls will be included (girls with onset of menstruation during the course of the trial are allowed to continue the treatment).

Children must be enrolled in a special need school, more specific a class comprising children with an intellectual disability or meet intellectual disability criteria; a total IQ below 75 and an ABAS score below 70

Exclusion Criteria

Patient activelytakes anti-epileptic medication or has an active medical problem like cardiac pathology or serious liver, renal problems which influence the metabolism of oxytocin (IMP)

Patient has a known syndrome that interacts with the reproductive hormonal system (e.g. Prader-Willi or Angelman syndrome)

Significant hearing or vision impairments

Subjects who have had previous chronic treatment with oxytocin

Participation in another clinical trial with IMP

Known hypersensitivity to active substance or ingredients of the nasal spray

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The Brief Observation of Social Communication Change (BOSCC) (clinician-rated)

The Brief Observation of Social Communication Change (BOSCC) (clinician-rated)

The Autism Treatment Evaluation Checklist (ATEC) (parent (caregiver) and teacher-rated)

The Autism Treatment Evaluation Checklist (ATEC) (parent (caregiver) and teacher-rated)

Recordings of electrocardiography (ECG) for the assessment of heart rate variability (HRV) during rest

Recordings of electrocardiography (ECG) for the assessment of heart rate variability (HRV) during rest

Secondary Outcome Measures
NameTimeMethod
The Repetitive Behavior Scale - Revised (RBS-R) (parent (caregiver) and teacher-rated)

The Repetitive Behavior Scale - Revised (RBS-R) (parent (caregiver) and teacher-rated)

The Adaptive Behavior Assessment System (ABAS-3) (parent (caregiver)-rated)

The Adaptive Behavior Assessment System (ABAS-3) (parent (caregiver)-rated)

The Developmental Behaviour Checklist (DBC) (parent (caregiver)-rated)

The Developmental Behaviour Checklist (DBC) (parent (caregiver)-rated)

The Perceived Stress Scale (PSS) (parent (caregiver)-rated)

The Perceived Stress Scale (PSS) (parent (caregiver)-rated)

The Child’s Sleep Habits Questionnaire Abbreviated (CSHQ-A) (parent (caregiver)-rated)

The Child’s Sleep Habits Questionnaire Abbreviated (CSHQ-A) (parent (caregiver)-rated)

Trial Locations

Locations (1)

UZ Leuven

🇧🇪

Leuven, Belgium

UZ Leuven
🇧🇪Leuven, Belgium
Edward Debbaut
Site contact
+3216343821
edward.debbaut@kuleuven.be

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.